Cabaletta Bio, Inc. (CABA)

Market Cap	110.46M
Revenue (ttm)	n/a
Net Income (ttm)	-104.16M
Shares Out	48.88M
EPS (ttm)	-2.16
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	2,472,861
Open	2.560
Previous Close	2.540
Day's Range	2.180 - 2.620
52-Week Range	2.180 - 26.350
Beta	2.42
Analysts	Strong Buy
Price Target	28.50 (+1,161.06%)
Earnings Date	Nov 14, 2024

About CABA

Cabaletta Bio, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases. The company’s lead product candidate is CABA-201, a fully human anti-CD19 binder for the treatment of Phase 1/2 clinical trials in dermatomyositis, anti-synthetase syndrome, immune-mediated necrotizing myopathy, lupus nephritis, non-renal systemic lupus erythematosus, systemic sclerosis, and generalized myasthenia gravis. It also develops DSG3-CAART, which is ...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Oct 25, 2019
• Employees: 103
• Stock Exchange: NASDAQ
• Ticker Symbol: CABA
• Website: https://www.cabalettabio.com

Analyst Forecast

According to 10 analysts, the average rating for CABA stock is "Strong Buy." The 12-month stock price forecast is $28.5, which is an increase of 1,161.06% from the latest price.

Price Target

$28.5

(1,161.06% upside)

Analyst Consensus: Strong Buy